KMDA

Kamada Ltd. (KMDA) | Rumor.io

Kamada

KMDA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,603

Bullish sentiment (50-day avg)100%

Price to earnings ratio22.7

Market capitalization497.5M

Earnings per share0.38

Dividend yield (TTM)7.89%

Revenue (annual)180.5M

Net income (annual)20.2M

Social

What share of all stock conversation is about KMDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 11

Kamada Ltd. has declared a cash dividend of $0.25 per share, payable on April 6, 2026, to shareholders of record at the close of business on March 23, 2026.
The company has reported record 2025 financial results, with total revenues of $180.5 million, a 12% year-over-year increase, and record adjusted EBITDA of $42.0 million, up 23% year-over-year.
Kamada has affirmed its 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, representing 13% and 23% growth, respectively, compared to 2025 results.

Generated by AI

Sentiment

Of the messages about KMDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.09% +4.84
Bearish	—	—	—	2.91% -4.84

Dec 6

$KMDA's deal with Kedrion is a significant catalyst, and the company is still undervalued despite a 20% price increase.
The stock's commercial agreement with Kedrion is expected to generate $180M in revenue over the first four years, with a 61% gross profit margin.
$KMDA's EPS per quarter could increase to around 18 cents due to the addition of $11.25M in quarterly net income from the Kedrion deal.

Generated by AI

Topics

Of the messages about KMDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	92.24%
Earnings	—	—	0%	7.76%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Earnings· Aug 7

Kamada Ltd. ($KMDA) beats earnings estimates with a $0.14 EPS report, surpassing the consensus of $0.09.
The company's revenue for FQ2 was $33.84M, exceeding the Estimize Revenue Consensus by $2.70M.
Kamada's earnings report for Q2 was mixed, with the company beating EPS estimates but missing overall estimates.

Announcements· Dec 6

Kamada Ltd. (KMDA) has announced its largest commercial agreement with Kedrion for the U.S. distribution of KEDRAB, with expected revenues of $180 million over the first four years.
The agreement is an eight-year term, starting in January 2024, with Kedrion purchasing minimum quantities of KEDRAB and generating significant revenues for Kamada.
Kamada's CEO, Amir London, stated that the partnership maximizes the future growth and value potential of KEDRAB, with Kedrion's extensive market coverage and success in marketing KEDRAB in the U.S. contributing to the agreement's significance.

Generated by AI

Community

Of the messages about KMDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	65.22%	66.44%
Newcomers	—	—	34.78%	33.56%

Regulars· Dec 6

Kamada Ltd. announced a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB U.S. distribution agreement, with $180 million in expected revenues over the first four years.
The agreement is Kamada's largest commercial deal, and the company is still undervalued despite its recent stock price jump.
The deal's execution is expected to trigger purchases of $20-$25 million, potentially leading to Kamada's inclusion in leading Israeli indexes and increasing its market capitalization.

Newcomers· Dec 6

Newcomers are focusing on Kamada Ltd.'s significant price increase, with $KMDA up 19.63% and 18% in the pre-market.
The largest commercial agreement between Kamada Ltd. and Kedrion for U.S. distribution of KEDRAB is generating $180 million in revenues over the first four years.
There is suspicion among newcomers about a firm's $100 million position in $KMDA, raising questions about the motivations behind this investment.

Generated by AI

A notable acquisition unfolded on September 29, as Botzer, Board Member at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 60,000 shares in an SEC filing. What Happened: A Form 4 filing from the U.S.

21h agoBenzinga

Significant Move: Ishay Davidi Invests $162K In Kamada Stock Options - Kamada (NASDAQ:KMDA)

A notable acquisition unfolded on September 29, as Davidi, Board Member at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 86,500 shares in an SEC filing. What Happened: Davidi, Board Member at

21h agoBenzinga

Director At Kamada Acquires Company Stock Options Worth $162K - Kamada (NASDAQ:KMDA)

Disclosed in a recent SEC filing, Lilach Asher Topilsky, Director at Kamada (NASDAQ:KMDA), made a strategic move by acquiring company stock options on September 29,. What Happened: Disclosed in a Form 4 filing on

21h agoBenzinga

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

Kamada (NASDAQ:KMDA) outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand through product sales, distribution agreements, plasma supply and potential acquisitions. The comp

3d agoYahoo Finance

Big News: Lilach Payorski Adds $136K In Kamada Stock Options Io Portfolio - Kamada (NASDAQ:KMDA)

A noteworthy insider acquisition was disclosed on September 24, as Payorski, Director at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 60,000 shares. What Happened: Payorski, Director at Kamada,

4d agoBenzinga

Insider Decision Making Waves At Kamada: Boris Gorelik Exercises Options, Realizing $0 - Kamada (NASDAQ:K

A significant insider transaction involving the exercise of company stock options was reported on September 24, by Boris Gorelik, VP at Kamada (NASDAQ:KMDA), as per the latest SEC filing. What Happened: Disclosed in a

4d agoBenzinga

Also Discussed

Investors talking about KMDA also mention

#	Name	Attention
1	MediWound Ltd.MDWD	0%0
2	Grifols S.A. ADRGRFS	0%0
3	RedHill Biopharma Ltd. American Depositary SharesRDHL	0%0
4	BioLine RX LtdBLRX	0%0
5	DVAX - Dynavax Technologies Corporation	——
6	ADMA Biologics, Inc.ADMA	0%+0
7	MYOV - Myovant Sciences Ltd.	——
8	CTIC - CTI BioPharma Corp.	——
9	MGIC - Magic Software Enterprises Ltd.	——
10	Verrica Pharmaceuticals Inc.VRCA	0%0

Kamada Ltd.

Healthcare
Drug Manufacturers - Specialty & Generic

Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapeutics. Kamada Ltd. develops, manufactures, and markets a portfolio of marketed products for rare and serious conditions, with treatments used in areas such as lung disease, immunology, infectious disease prophylaxis, and critical care. The company’s commercial offering includes proprietary plasma-derived therapies and a distribution segment that markets additional biopharmaceutical products in selected international markets. Kamada Ltd. also operates manufacturing capabilities centered on plasma protein purification and sterile production, supporting its vertically integrated business model. Its products are sold through partners, distributors, hospitals, pharmacies, and healthcare organizations across multiple countries, making the company a specialized supplier within the global plasma therapeutics market.

Website

Location

2 Holzman Street

Rehovot, 7670402

Israel

Social

What share of all stock conversation is about KMDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 11

Kamada Ltd. has declared a cash dividend of $0.25 per share, payable on April 6, 2026, to shareholders of record at the close of business on March 23, 2026.
The company has reported record 2025 financial results, with total revenues of $180.5 million, a 12% year-over-year increase, and record adjusted EBITDA of $42.0 million, up 23% year-over-year.
Kamada has affirmed its 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, representing 13% and 23% growth, respectively, compared to 2025 results.

Generated by AI

Sentiment

Of the messages about KMDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.09% +4.84
Bearish	—	—	—	2.91% -4.84

Dec 6

$KMDA's deal with Kedrion is a significant catalyst, and the company is still undervalued despite a 20% price increase.
The stock's commercial agreement with Kedrion is expected to generate $180M in revenue over the first four years, with a 61% gross profit margin.
$KMDA's EPS per quarter could increase to around 18 cents due to the addition of $11.25M in quarterly net income from the Kedrion deal.

Generated by AI

Topics

Of the messages about KMDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	92.24%
Earnings	—	—	0%	7.76%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Earnings· Aug 7

Kamada Ltd. ($KMDA) beats earnings estimates with a $0.14 EPS report, surpassing the consensus of $0.09.
The company's revenue for FQ2 was $33.84M, exceeding the Estimize Revenue Consensus by $2.70M.
Kamada's earnings report for Q2 was mixed, with the company beating EPS estimates but missing overall estimates.

Announcements· Dec 6

Kamada Ltd. (KMDA) has announced its largest commercial agreement with Kedrion for the U.S. distribution of KEDRAB, with expected revenues of $180 million over the first four years.
The agreement is an eight-year term, starting in January 2024, with Kedrion purchasing minimum quantities of KEDRAB and generating significant revenues for Kamada.
Kamada's CEO, Amir London, stated that the partnership maximizes the future growth and value potential of KEDRAB, with Kedrion's extensive market coverage and success in marketing KEDRAB in the U.S. contributing to the agreement's significance.

Generated by AI

Community

Of the messages about KMDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	65.22%	66.44%
Newcomers	—	—	34.78%	33.56%

Regulars· Dec 6

Kamada Ltd. announced a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB U.S. distribution agreement, with $180 million in expected revenues over the first four years.
The agreement is Kamada's largest commercial deal, and the company is still undervalued despite its recent stock price jump.
The deal's execution is expected to trigger purchases of $20-$25 million, potentially leading to Kamada's inclusion in leading Israeli indexes and increasing its market capitalization.

Newcomers· Dec 6

Newcomers are focusing on Kamada Ltd.'s significant price increase, with $KMDA up 19.63% and 18% in the pre-market.
The largest commercial agreement between Kamada Ltd. and Kedrion for U.S. distribution of KEDRAB is generating $180 million in revenues over the first four years.
There is suspicion among newcomers about a firm's $100 million position in $KMDA, raising questions about the motivations behind this investment.

Generated by AI

Kamada

Social

Mar 11

Sentiment

Dec 6

Topics

Earnings· Aug 7

Announcements· Dec 6

Community

Regulars· Dec 6

Newcomers· Dec 6

News

Strategic Investment: Uri Botzer Boosts Portfolio With $148K In Kamada Stock Options - Kamada (NASDAQ:KMD

Significant Move: Ishay Davidi Invests $162K In Kamada Stock Options - Kamada (NASDAQ:KMDA)

Director At Kamada Acquires Company Stock Options Worth $162K - Kamada (NASDAQ:KMDA)

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

Big News: Lilach Payorski Adds $136K In Kamada Stock Options Io Portfolio - Kamada (NASDAQ:KMDA)

Insider Decision Making Waves At Kamada: Boris Gorelik Exercises Options, Realizing $0 - Kamada (NASDAQ:K

Also Discussed

Kamada Ltd.

Company Information

Location

News

Strategic Investment: Uri Botzer Boosts Portfolio With $148K In Kamada Stock Options - Kamada (NASDAQ:KMD

Significant Move: Ishay Davidi Invests $162K In Kamada Stock Options - Kamada (NASDAQ:KMDA)

Director At Kamada Acquires Company Stock Options Worth $162K - Kamada (NASDAQ:KMDA)

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

Big News: Lilach Payorski Adds $136K In Kamada Stock Options Io Portfolio - Kamada (NASDAQ:KMDA)

Insider Decision Making Waves At Kamada: Boris Gorelik Exercises Options, Realizing $0 - Kamada (NASDAQ:K

Also Discussed

Social

Mar 11

Sentiment

Dec 6

Topics

Earnings· Aug 7

Announcements· Dec 6

Community

Regulars· Dec 6

Newcomers· Dec 6